PMID- 37600026
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230823
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 10
DP  - 2023
TI  - Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular 
      disease applications: a review of preclinical advancements.
PG  - 1236345
LID - 10.3389/fcvm.2023.1236345 [doi]
LID - 1236345
AB  - Cardiovascular diseases (CVD) continue to be the leading cause of morbidity and 
      mortality globally and claim the lives of over 17 million people annually. 
      Current management of CVD includes risk factor modification and preventative 
      strategies including dietary and lifestyle changes, smoking cessation, medical 
      management of hypertension and cholesterol lipid levels, and even surgical 
      revascularization procedures if needed. Although these strategies have shown 
      therapeutic efficacy in reducing major adverse cardiovascular events such as 
      heart attack, stroke, symptoms of chronic limb-threatening ischemia (CLTI), and 
      major limb amputation significant compliance by patients and caregivers is 
      required and off-target effects from systemic medications can still result in 
      organ dysfunction. Stem cell therapy holds major potential for CVD applications 
      but is limited by the low quantities of cells that are able to traffic to and 
      engraft at diseased tissue sites. New preclinical investigations have been 
      undertaken to modify mesenchymal stem cells (MSCs) to achieve targeted cell 
      delivery after systemic administration. Although previous reviews have focused 
      broadly on the modification of MSCs for numerous local or intracoronary 
      administration strategies, here we review recent preclinical advances related to 
      overcoming challenges imposed by the high velocity and dynamic flow of the 
      circulatory system to specifically deliver MSCs to ischemic cardiac and 
      peripheral tissue sites. Many of these technologies can also be applied for the 
      targeted delivery of other types of therapeutic cells for treating various 
      diseases.
CI  - (c) 2023 Huerta, Voza, Ortiz, Liu and Velazquez.
FAU - Huerta, Carlos Theodore
AU  - Huerta CT
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Voza, Francesca A
AU  - Voza FA
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Ortiz, Yulexi Y
AU  - Ortiz YY
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Liu, Zhao-Jun
AU  - Liu ZJ
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
AD  - Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, 
      FL, United States.
AD  - Department of Biochemistry & Molecular Biology, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Velazquez, Omaida C
AU  - Velazquez OC
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
AD  - Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, 
      FL, United States.
AD  - Department of Biochemistry & Molecular Biology, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230804
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC10436297
OTO - NOTNLM
OT  - cardiovascular disease
OT  - cell-based therapy
OT  - chronic limb-threatening ischemia
OT  - mesenchymal stem cell
OT  - myocardial infarction
OT  - stem cell therapy
OT  - targeted cell delivery
COIS- ZJ-L and OV declared the following potential conflicts of interest with respect 
      to the research, authorship, and/or publication of this article: the E-selectin 
      gene modification technologies described in referenced articles by ZJ-L and OV 
      were developed in our research laboratory and patented/Licensed by the University 
      of Miami. This technology is currently under pre-clinical development by Ambulero 
      Inc., a new start-up company out of the University of Miami that focuses on 
      developing new vascular treatments for ischemic conditions. Co-authors, ZJ-L and 
      OV, serve as consultants and scientific and medical advisory officers in Ambulero 
      Inc. OV and ZJ-L are co-inventors, co-principal investigators funded by the NIH 
      and are minority share holders in Ambulero Inc. The remaining authors declare 
      that the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2023/08/21 06:42
MHDA- 2023/08/21 06:43
PMCR- 2023/01/01
CRDT- 2023/08/21 04:39
PHST- 2023/06/07 00:00 [received]
PHST- 2023/07/25 00:00 [accepted]
PHST- 2023/08/21 06:43 [medline]
PHST- 2023/08/21 06:42 [pubmed]
PHST- 2023/08/21 04:39 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2023.1236345 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2023 Aug 4;10:1236345. doi: 10.3389/fcvm.2023.1236345. 
      eCollection 2023.